(Alliance News) - Cambridge Nutritional Sciences PLC and Novacyt SA on Tuesday noted legal action was underway with regard to subsidiary related activities concerning the use of biological agents.
Biotechnology group Novacyt, which has offices in Surrey, England and Velizy-Villacoublay, France said its non-trading subsidiary, Lab 21 Healthcare Ltd, has been charged with health and safety offences relating to the use of biological agents at a facility it used to operate in Axminster, Devon.
According to the firm, the lease for the site was taken over by Lab 21 from Omega Diagnostics Ltd as part of its 2018 acquisition of Omega's infectious disease business.
Novacyt said the operations subject to the charges no longer form any part of its ongoing business.
London-based medical diagnostics firm Cambridge Nutritional Sciences on Tuesday released a statement noting that it had received a court summons for its subsidiary Omega Diagnostics Ltd, relating to an alleged historical breach of HSE regulations.
The firm said the alleged breach occurred in 2018 and relates to the possession and use of biological agents at a small facility being used by Omega South West, a company previously owned by Omega Diagnostics and sold in 2018.
Cambridge Nutritional Sciences said the facility in question was sold in 2018, the same year in which Omega South West ceased all trading activities. It said the entity has not formed any part of its ongoing operations, with no existing employees having had any involvement with Omega South West.
Both Novacyt and Cambridge Nutritional Sciences noted a court hearing has been set for March 18 of this year.
The firms stated they will make further announcements in due course.
Both shares were down at London close with Cambridge Nutritional Sciences closing down 5.1% at 3.70 pence and Novacyt shares down 6.7% at 52.60p.
By Christopher Ward, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2025 Alliance News Ltd. All Rights Reserved.